(Q37166804)

English

Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation

scientific article published on May 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

0 references

osteogenesis imperfecta

0 references

1 reference

based on heuristic

inferred from title

Gloria Gronowicz

6

object named as

Gloria Gronowicz

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

author name string

Thomas E Uveges

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Kenneth M Kozloff

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Jennifer M Ty

3

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Felicia Ledgard

4

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Cathleen L Raggio

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Steven A Goldstein

7

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Joan C Marini

8

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

publication date

1 May 2009

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Journal of Bone and Mineral Research

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

24

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

849-859

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Economic return of clinical trials performed under the pediatric exclusivity program

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

6 September 2017

Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

6 September 2017

Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

6 September 2017

The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

6 September 2017

Use of the Cre/lox recombination system to develop a non-lethal knock-in murine model for osteogenesis imperfecta with an alpha1(I) G349C substitution. Variability in phenotype in BrtlIV mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

6 September 2017

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

6 September 2017

Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

6 September 2017

Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

6 September 2017

Comparison of the trabecular and cortical tissue moduli from human iliac crests

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

28 September 2017

Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

27 June 2018

Osteoprotegerin Regulates Bone Formation through a Coupling Mechanism with Bone Resorption

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

27 June 2018

Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

3 September 2018

Early bisphosphonate treatment in infants with severe osteogenesis imperfecta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

3 September 2018

Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

3 September 2018

Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

3 September 2018

Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

3 September 2018

Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

3 September 2018

Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

3 September 2018

Brittle IV mouse model for osteogenesis imperfecta IV demonstrates postpubertal adaptations to improve whole bone strength

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

3 September 2018

Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

3 September 2018

Bisphosphonate-induced osteopetrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

3 September 2018

Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

3 September 2018

Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

3 September 2018

Intravenous bisphosphonate therapy in children with osteogenesis imperfecta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

3 September 2018

Fourier transform infrared imaging spectroscopy (FT-IRIS) of mineralization in bisphosphonate-treated oim/oim mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

3 September 2018

Effect of cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta. Open-label study in seven patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

3 September 2018

Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

3 September 2018

Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

3 September 2018

A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

3 September 2018

Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2672204

3 September 2018

Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta

1 reference

https://pubmed.ncbi.nlm.nih.gov/19113917

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prolonged bisphosphonate release after treatment in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/19113917

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age

1 reference

https://pubmed.ncbi.nlm.nih.gov/19113917

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Do bisphosphonates make children's bones better or brittle?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19113917

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravenous pamidronate treatment in osteogenesis imperfecta

1 reference

https://pubmed.ncbi.nlm.nih.gov/19113917

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravenous Neridronate in Children With Osteogenesis Imperfecta: A Randomized Controlled Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19113917

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1359/JBMR.081238

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37166804&oldid=2174144219"